ANZONAT 1mg Tablets

Active Ingredients: Anastrozole

Strength: 1mg

Dosage Form:  Tablets

Retail Pack: 30 tablets in a carton

Indications: Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal
women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic
breast cancer.

LENTRONAT 2.5mg Tablets

Active Ingredients: Anastrozole

Strength: 1mg

Dosage Form:  Tablets

Retail Pack: 30 tablets in a carton

Indications:

• Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.
• Extended adjuvant treatment of invasive early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy for five years.
• First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.
• Treatment of advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endorcrine status, who have previ – ously been treated with anti-oestrogens.

EMENAT 1mg Tablets

Active Ingredients: Granisetron Hydrochloride

Strength: 1mg

Dosage Form:  Tablets

Retail Pack: 20 tablets in a carton

Indication: Granisetron hydrochloride is indicated for the prevention of nausea and vomiting
induced by cytostatic therapy.

XPREZA 100mg Vial

Active Ingredients:Azacitidine

Strength: 100mg

Dosage Form:  Injectable

Retail Pack: 1 vial in a carton

Indication:

Xpreza is indicated for the treatment of adult patients who are not eligible for haema¬topoietic stem cell transplantation with:
• intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
• chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder, acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification.

BEMUNAT 100mg Vial

Active Ingredients: Bendamustine Hydrochloride

Strength: 100mg

Dosage Form:  Injectable

Retail Pack: 1 vial in a carton

Indication:

• • Chronic Lymphocytic Leukemia (CLL)

Bendamustine hydrochloride for infusion is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established.

• • Non-Hodgkin’s Lymphoma (NHL)

Bendamustine hydrochloride for infusion is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

BEMUNAT 25mg Vial

Active Ingredients:Bendamustine Hydrochloride

Strength: 25mg

Dosage Form: Injectable

Retail Pack: 1 vial in a carton

Indications:

• • Chronic Lymphocytic Leukemia (CLL)

Bendamustine hydrochloride for infusion is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established.

• • Non-Hodgkin’s Lymphoma (NHL)

Bendamustine hydrochloride for infusion is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

ZOLDONAT 4mg/5mlVial

Active Ingredients:Zoledronic Acid

Strength: 4mg/5ml

Dosage Form: Injectable

Retail Pack: 1 vial in a carton

Indications:

• Treatment of osteolytic, osteoblastic, and mixed bone metastases of solid tumours and osteolytic lesions of multiple myeloma, in conjunction with standard antineoplastic therapy.
• Treatment of hypercalcaemia of malignancy (HCM).

VEENAT 100mg Tablets

Active Ingredients:Imatinib Mesylate

Strength: 100mg

Dosage Form:  Tablets

Retail Pack: 90 tablets in a bottle

Indications:

• Philadelphia chromosome positive chronic myeloid leukaemia (“Ph+ CML”);
• Ph+ CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy;
• Paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (“Ph+ ALL”) integrated with chemotherapy; and
• Adult patients with relapsed or refractory Ph+ ALL as monotherapy.>

VEENAT 400mg Tablets

Active Ingredients:Imatinib Mesylate

Strength: 400mg

Dosage Form:  Tablets

Retail Pack: 30 tablets in a bottle

Indications:

• Philadelphia chromosome positive chronic myeloid leukaemia (“Ph+ CML”);
• Ph+ CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy;
• Paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (“Ph+ ALL”) integrated with chemotherapy; and
• Adult patients with relapsed or refractory Ph+ ALL as monotherapy.